Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
sanofi-aventis (formerly Sanofi-Synthelabo) is developing the oral class III anti-arrhythmic agent dronedarone (Multaq) for the potential treatment and prevention of atrial fibrillation. In June 2005, sanofi-aventis submitted EU and US filings for atrial fibrillation. In October 2002, phase I trials for arrhythmia were reported to be ongoing in Japan.